Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
Unlike goserelin, leuprorelin and triptorelin have not been assessed for their impact on survival in patients with locally advanced prostate cancer. The main adverse effects of these two drugs are similar, but convenience of use differs.